TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to optimize several multi-dose regimens of otelixizumab,
determine the highest biologically active dose, evaluate biomarkers and surrogates of
efficacy, and to evaluate the effects of each multi-dose regimen of otelixizumab against
standard safety and efficacy parameters.